Research Analysts Issue Forecasts for Abbott Laboratories' Q1 2023 Earnings (NYSE:ABT)
Research Analysts Issue Forecasts for Abbott Laboratories' Q1 2023 Earnings (NYSE:ABT)
Abbott Laboratories (NYSE:ABT – Get Rating) – William Blair cut their Q1 2023 EPS estimates for shares of Abbott Laboratories in a report released on Thursday, January 26th. William Blair analyst M. Kaczor now anticipates that the healthcare product maker will post earnings per share of $0.97 for the quarter, down from their previous forecast of $0.99. The consensus estimate for Abbott Laboratories' current full-year earnings is $4.37 per share. William Blair also issued estimates for Abbott Laboratories' Q2 2023 earnings at $1.03 EPS.
雅培(紐約證券交易所代碼:ABT-GET Rating)-威廉·布萊爾在1月26日週四發佈的一份報告中下調了對雅培股票2023年第一季度每股收益的預期。威廉·布萊爾分析師M.Kaczor現在預計,這家醫療保健產品製造商將公佈本季度每股收益為0.97美元,低於此前預測的0.99美元。市場普遍預計雅培目前的全年收益為每股4.37美元。威廉·布萊爾還發布了雅培2023年第二季度每股收益1.03美元的預測。
Abbott Laboratories (NYSE:ABT – Get Rating) last posted its quarterly earnings data on Wednesday, January 25th. The healthcare product maker reported $1.03 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.13. The firm had revenue of $10.09 billion during the quarter, compared to analysts' expectations of $9.69 billion. Abbott Laboratories had a net margin of 15.88% and a return on equity of 26.24%. The company's quarterly revenue was down 12.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.32 EPS.
雅培(紐約證券交易所代碼:ABT-GET Rating)最近一次發佈季度收益數據是在1月25日星期三。這家保健品製造商公佈本季度每股收益為1.03美元,比普遍預期的0.90美元高出0.13美元。該公司本季度營收為100.9億美元,高於分析師預期的96.9億美元。雅培的淨利潤率為15.88%,股本回報率為26.24%。與去年同期相比,該公司的季度收入下降了12.0%。去年同期,該公司公佈的每股收益為1.32美元。
Abbott Laboratories Trading Down 1.0 %
雅培股價下跌1.0%
ABT opened at $109.95 on Friday. Abbott Laboratories has a 1-year low of $93.25 and a 1-year high of $130.93. The firm has a 50-day moving average price of $109.07 and a two-hundred day moving average price of $105.86. The company has a current ratio of 1.86, a quick ratio of 1.43 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $191.71 billion, a PE ratio of 28.20, a PEG ratio of 5.06 and a beta of 0.69.
ABT上週五開盤報109.95美元。雅培的一年低點為93.25美元,一年高位為130.93美元。該公司的50日移動均線價格為109.07美元,200日移動均線價格為105.86美元。該公司的流動比率為1.86,速動比率為1.43,債務權益比率為0.43。該股市值為1,917.1億美元,市盈率為28.20倍,市盈率為5.06倍,貝塔係數為0.69。
Abbott Laboratories Increases Dividend
雅培增加分紅
The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 15th. Investors of record on Friday, January 13th will be issued a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a yield of 1.86%. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.47. The ex-dividend date of this dividend is Thursday, January 12th. Abbott Laboratories's payout ratio is presently 52.17%.
該公司最近還宣佈了季度股息,將於2月15日(星期三)支付。1月13日(星期五)登記在冊的投資者將獲得每股0.51美元的股息。這意味着年化股息為2.04美元,收益率為1.86%。這比雅培之前季度派息0.47美元有所增加。本次股息除息日期為1月12日星期四。雅培目前的派息率為52.17%。
Insider Buying and Selling
內幕買賣
In related news, EVP John F. Ginascol sold 11,000 shares of the business's stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $112.32, for a total transaction of $1,235,520.00. Following the transaction, the executive vice president now directly owns 111,912 shares in the company, valued at $12,569,955.84. The sale was disclosed in a filing with the SEC, which is available through this link. 0.52% of the stock is owned by corporate insiders.
在相關新聞中,執行副總裁約翰·F·吉納斯科在12月13日(星期二)的一次交易中出售了1.1萬股該公司的股票。這些股票以112.32美元的平均價格出售,總成交金額為1235520.00美元。交易完成後,執行副總裁總裁現在直接持有該公司111,912股股份,價值12,569,955.84美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節。0.52%的股份由企業內部人士持有。
Hedge Funds Weigh In On Abbott Laboratories
對衝基金看好雅培
Several institutional investors and hedge funds have recently modified their holdings of ABT. Insight Inv LLC acquired a new position in shares of Abbott Laboratories in the second quarter valued at $26,000. JDM Financial Group LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at about $26,000. EdgeRock Capital LLC acquired a new position in shares of Abbott Laboratories in the third quarter valued at about $29,000. Johnson Midwest Financial LLC grew its stake in shares of Abbott Laboratories by 28.7% in the third quarter. Johnson Midwest Financial LLC now owns 560 shares of the healthcare product maker's stock valued at $35,000 after acquiring an additional 125 shares in the last quarter. Finally, Arcus Capital Partners LLC acquired a new position in shares of Abbott Laboratories in the fourth quarter valued at about $35,000. 72.93% of the stock is currently owned by institutional investors and hedge funds.
幾家機構投資者和對衝基金最近調整了對ABT的持股。Insight Inv LLC在第二季度收購了雅培的新股票頭寸,價值26,000美元。JDM Financial Group LLC在第四季度收購了雅培的新頭寸,價值約26,000美元。EdgeRock Capital LLC在第三季度收購了雅培的新頭寸,價值約29,000美元。約翰遜中西部金融有限責任公司第三季度增持雅培股份28.7%。Johnson Midwest Financial LLC在上個季度增持了125股後,現在持有這家醫療保健產品製造商560股股票,價值3.5萬美元。最後,Arcus Capital Partners LLC在第四季度收購了雅培的新頭寸,價值約35,000美元。72.93%的股票目前由機構投資者和對衝基金持有。
About Abbott Laboratories
關於雅培
(Get Rating)
(獲取評級)
Abbott Laboratories engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. It operates through the following segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products.
雅培致力於發現、開發、製造和銷售廣泛而多樣化的保健品系列。它通過以下細分市場運作:成熟的醫藥產品、營養產品、診斷產品和醫療設備。已建立的醫藥產品部門是指一系列品牌仿製藥產品的國際銷售。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Abbott Laboratories (ABT)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- 免費獲取斯托克新聞網關於雅培的研究報告(ABT)
- 市場回顧周-1/23-1/27
- 為什麼Lucid在一天內飆升了近100%
- 利用這些鐵路股票實現增長和收入
- ASML預計今年芯片需求回升,提振銷售觀點
- KLA公司:在動盪不安的半市場中站穩腳跟
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
接受《雅培日報》的新聞和評級-在下面輸入您的電子郵件地址,即可通過MarketBeat.com的免費每日電子郵件時事通訊接收對雅培及相關公司的最新新聞和分析師評級的每日摘要。